Neuronetics, Inc. (STIM)

NGM – Цена в реальном времени. Валюта: USD

3.21

+0.03 (0.78%)

Рынок открыт: Aug 12, 2026, 1:47 PM EDT

3.21

+0.02 (0.63%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

11.08.2026

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

11.08.2026

Neuronetics Q2 Earnings Call Highlights

Neuronetics NASDAQ: STIM reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced additional commercial purchasing options for its NeuroStar transcranial magnetic stimulation, or TMS, systems.

11.08.2026

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.

03.08.2026

Neuronetics and Jorey Chernett Announce Shared Vision

MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company's second largest shareholder and Managing Member of Pointillist Family Office, today announced that they have created a constructive framework for alignment between the Company's Board of Directors (the “Board”), management, and Mr. Chernett (the “Understanding”).

31.07.2026

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to five new non-executive employees as described below.

Видео

No Data

There is no data to display

Пресс-релизы

03.08.2026

Neuronetics and Jorey Chernett Announce Shared Vision

31.07.2026

Neuronetics, Inc. (STIM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Neuronetics, Inc. (STIM)

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

Neuronetics Q2 Earnings Call Highlights

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

Neuronetics Q2 Earnings Call Highlights

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Neuronetics, Inc. (STIM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Neuronetics, Inc. (STIM)

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

Neuronetics Q2 Earnings Call Highlights

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

Neuronetics Q2 Earnings Call Highlights

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)